<code id='20BA42E919'></code><style id='20BA42E919'></style>
    • <acronym id='20BA42E919'></acronym>
      <center id='20BA42E919'><center id='20BA42E919'><tfoot id='20BA42E919'></tfoot></center><abbr id='20BA42E919'><dir id='20BA42E919'><tfoot id='20BA42E919'></tfoot><noframes id='20BA42E919'>

    • <optgroup id='20BA42E919'><strike id='20BA42E919'><sup id='20BA42E919'></sup></strike><code id='20BA42E919'></code></optgroup>
        1. <b id='20BA42E919'><label id='20BA42E919'><select id='20BA42E919'><dt id='20BA42E919'><span id='20BA42E919'></span></dt></select></label></b><u id='20BA42E919'></u>
          <i id='20BA42E919'><strike id='20BA42E919'><tt id='20BA42E919'><pre id='20BA42E919'></pre></tt></strike></i>

          explore

          explore

          author:Wikipedia    Page View:627
          Illustration of two DNA strands made of banknotes. -- health coverage from STAT
          Adobe

          The staff of the Institute for Clinical and Economic Review, or ICER, are known as the nerds of the drug industry: bespectacled killjoys who emerge a few times a year to scold drugmakers for pricing their latest cancer or MS advance far beyond reason.

          But last year, they sat down and concluded a forthcoming treatment was worth up to $3.9 million — more than any medicine in history, more than a 45-year supply of Humira, the autoimmune drug often held up as an emblem of America’s runaway drug spending. 

          advertisement

          It was a testament to the power of a new class of gene therapies to deliver something pharma so rarely does: Genuine cures. The treatment, approved last week as Lenmeldy, may allow some babies born with an ultra-rare neurodegenerative disease called metachromatic leukodystrophy, or MLD, to grow up and live essentially normal lives.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge

          How one medical school became remarkably diverse
          How one medical school became remarkably diverse

          ThefirstclassattheUniversityofCalifornia,Davismedicalschool,in1972,waspredominantlywhiteandmale.Chri

          read more
          Medicare Advantage beneficiaries sue Humana over algorithm use
          Medicare Advantage beneficiaries sue Humana over algorithm use

          AdobeMedicareAdvantagebeneficiariesonTuesdayfiledaclass-actionlawsuitallegingthatthehealthinsuranceg

          read more
          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more

          Bristol Myers buys into radiopharmaceuticals with RayzeBio

          CourtesyBristolMyersSquibbBristolMyersSquibbwillpay$4.1billionforRayzeBio,thecompaniessaidTuesday,bu